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ABSTRACT 
For many years, the oral combination melphalan-prednisone (MP) has been considered the standard 
of care for patients with multiple myeloma (MM) not eligible for autologous stem cell 
transplantation. In the era of novel agents, the introduction of immunomodulatory drugs and 
proteasome inhibitors has challenged the role of MP and lead to new standards of care for this 
disease. Five randomized phase III studies compared the traditional MP with the MP plus 
thalidomide (MPT). All these studies showed a prolonged time to progression (TTP) with the 3-
drug combination. However, in only two of these trials this advantage translated into an 
improvement in overall survival (OS). In another randomized trial, MP plus bortezomib (VMP) was 
correlated with an increase in both TTP and OS compared with MP. Preliminary data showed the 
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superiority of the association of VMP plus thalidomide followed by bortezomib-thalidomide 
maintenance (VMPT-VT) vs VMP and melphalan-prednisone-lenalidomide followed by 
lenalidomide maintenance (MPR-R) compared to MP. Promising results have also been reported 
with the combination of lenalidomide plus low-dose dexamethasone. The availability of different 
efficacious regimens provided clinicians with the opportunity of tailoring the proper and specific 
approach for each patient. The choice should be based on patients' comorbidities and biologic age, 
while taking into account the expected toxicity profiles of each treatment regimen. Moreover, an 
accurate management of therapy-related adverse events and a gentler approach, particularly for 
patients older than 75 years, with appropriate age-adjusted dose reductions, should be considered to 
further improve outcome. 
Epidemiology 
Multiple myeloma (MM) is an incurable plasma cell disease that comprises 1% of all 
cancers and 10% of hematologic neoplasms. It accounts for 20,580 new cancer cases in the USA in 
2009, including 11,680 cases in men, 8,900 cases in women, and 10,580 deaths overall.(1) The 
median age at diagnosis is 70 years, with 36% of patients younger than 65 years, 27% aged 65 to 74 
years , and 37% older than 75 years.(2,3) Considering the increasing life-expectancy of the normal 
population, the number of geriatric patients is expected to rise over time. 
 
Diagnosis and Treatment Strategy 
Recognizing organ damage and its correlation with MM is the very first step to correctly 
identify symptomatic disease and subsequently start treatment. MM is defined by the presence of 
monoclonal protein in the urine and/or serum, and bone-marrow plasma cells greater than 10%. 
When no monoclonal protein is detected, an abnormal serum free light-chain ratio is a further sign 
of MM.  
 4 
Symptomatic disease is characterized by evidence of end-organ damage caused by plasma 
cell proliferation, or CRAB features: C: hypercalcemia (>11.5 mg/dL [2.65 mmol/L]); R: renal 
failure (serum creatinine > 2 mg/dL [1.73 mmol/L]); A: anaemia (hemoglobin < 10 g/dL [12.5 
mmol/L] or > 2 g/dL [1.25 mmol/L] below the lower limit of normal); and B: bone disease (lytic 
lesions, severe osteopenia or pathologic fractures).(4,5)  
MM is staged according to the International Staging System (ISS). Patients may be 
classified in three different risk groups: Stage I, with a median survival of 62 months; patients in 
this group have serum β2-microglobulin < 3.5 mg/L and serum albumin ≥ 35 g/L. Stage II, with 
median survival of 44 months; patients in this category have serum β2-microglobulin < 3.5 mg/L 
and serum albumin < 35 g/L, or serum β2-microglobulin  3.5-5.5 mg/L. Stage III, with a median 
survival of 29 months; patients belonging to this stage have serum β2-microglobulin ≥ 5.5 mg/L.(6) 
Serum free light-chain incorporated into the ISS may improve the risk stratification.(7) 
Chromosomal abnormalities can be detected by using cytogenetics and fluorescent in-situ 
hybridization (FISH). The presence of 17p deletion (del 17) or t(4;14) or t(14;16) detected by FISH 
are associated with poorer outcome, hyperdiploid is associated with good outcome and t(11;14) 
does not have a negative impact. Patients with isolated deletion 13 (del13) on FISH analysis do not 
have a worse outcome, unless this abnormality is associated with (del17) or t(4;14).(8,9) (Table 1) 
Patients with symptomatic MM should be treated immediately; early intervention on 
asymptomatic patients showed no benefits, and observation alone is the standard.(10-12) 
Treatment choice should be based on both patient’s characteristics, in particular age, and 
scientific evidence. In many European countries, elderly patients (subjects older than 65 years) are 
generally considered ineligible for autologous stem cell transplantation (ASCT). However, 
biological age and chronological age do not always correspond, and a greater emphasis should be 
placed on the former rather than the latter. Beside age, other relevant factors play a fundamental 
role in determining whether a patient is eligible for ASCT or not, such as performance status and 
comorbidities. Patients are generally considered eligible for ASCT if they have normal cardiac, 
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pulmonary, liver and renal functions. However, reduced dose-intensity transplantation may be a 
valuable option for elderly patients up to the age of 75 in good clinical conditions. 
Physicians have different treatment options available for the management of MM. These 
treatments are defined as standard if they are supported by at least one randomized study reporting 
an improvement in progression-free survival (PFS); phase II studies are still considered valuable 
and of important scientific evidence, especially if results of phase III trials are not available. 
This paper will focus on the results of the latest phase III studies on transplant ineligible 
patients. In the past, patients who were not candidates for ASCT were usually treated with the oral 
combination melphalan-prednisone (MP). The introduction of novel agents, such as 
immunomodulatory drugs (IMIDs) (thalidomide and lenalidomide) and proteasome inhibitors 
(bortezomib), has substantially changed the treatment paradigm of MM.  
 
Therapeutic Options 
Melphalan and Prednisone: the old standard of care. 
For more than 40 years, the oral combination MP has been considered the standard of care 
for elderly patients with newly diagnosed MM, and for young patients who were not candidates for 
high-dose therapy. A meta-analysis of 27 randomized trials compared different chemotherapy 
regimens with MP: despite higher response rates reported with the different chemotherapy regimens 
(60.0% vs 53.2%, P < 0.0001) as compared to MP, no significant difference in overall survival (OS) 
was detected (P = 0.6) and MP showed to be better tolerated.(13) In a randomized trial comparing 
MP with melphalan plus dexamethasone (MD), high-dose dexamethasone (HD) and HD plus 
interferon-α, an improvement in response rate and PFS in patients receiving melphalan as part of 
the induction treatment (both MP and MD) did not translate into a survival advantage; the morbidity 
associated with dexamethasone-containing regimens (in particular severe pyogenic infections, 
haemorrhage, severe diabetes, gastrointestinal and psychiatric complications) was significantly 
higher, and MP was generally better tolerated (14).  
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Another randomized study comparing MP with thalidomide and dexamethasone (TD) 
showed higher response rate and longer PFS with TD. Nonetheless, patients receiving MP had a 
significantly longer survival, again probably due to the better tolerability of MP compared to TD: 
extra-hematological toxicities, mainly related to high-dose dexamethasone, were superior in patients 
treated with TD, leading to a higher treatment-discontinuation rate. During the first year of therapy, 
non-disease-related deaths in the TD group were twice as high as compared with those in the MP 
group, with infections being the primary cause. In patients older than 72 years with poor 
performance status, this difference was even more pronounced.(15) These results provided the 
rationale to combine the standard MP with novel agents thalidomide, bortezomib and lenalidomide. 
 
New regimens containing novel agents: 
Thalidomide-based therapies  
 Thalidomide plus MP (MPT). Five randomized studies compared the combination MPT 
with the standard MP: partial response (PR) rate was 42%-76% vs 28%-48% with MPT and MP 
respectively, at least very good PR (VGPR) or near complete response (nCR) rate was 15%-47% vs 
6%-8%, and PFS was 14-28 vs 10-19 months.(16-21) Although in the 2 Intergroupe Francophone 
du Myelome (IFM) studies, the PFS advantage observed with MPT also translated into a significant 
OS advantage (45-52 vs 28-32 months),(19,20) this was not confirmed in the three other trials.(16-
18,21) Despite this, results obtained with MPT suggest that the three-drug combination is far 
superior to the traditional MP. Therefore, today MPT is considered one of the standards of care for 
elderly patients.  
Recently a meta-analysis of pooled data of 1,682 patients from the MPT studies previously 
mentioned was performed. Median PFS was 20 (19-22) months in the MPT arm and 15 (14-17) 
months in the MP arm; median OS was 39 (35.6-39.0) months for patients who received MPT and 
33 (95% CI 30.4-36.5) months for patients treated with MP. Overall hazard ratio of MPT compared 
to MP was 0.67 (0.55-0.80) for PFS and 0.82 (0.66-1.02) for OS. This meta-analysis demonstrated a 
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significant advantage for PFS and is consistent with the difference in OS observed when 
thalidomide is added to MP in first-line treatment to elderly patients.(22) 
Grade 3-4 neutropenia mainly related to melphalan, was the main adverse event (AE) 
associated with MPT, ranging from 16% to 48%. As for the thalidomide-related AEs, peripheral 
neuropathy was reported in 6%-23% of patients treated with MPT and venous thromboembolism 
(VTE) in 3% to 12% of patients.(18-21) 
 Thalidomide plus cyclophosphamide and dexamethasone (CTD). The medical 
Research Council (MRC) Myeloma IX trial compared the CTD combination with the standard MP 
in a randomized trial including 900 patients. Higher responses were seen in patients treated with  
CTD as compared to MP: at least PR rate was 83% vs 46%, and CR rate was 21% vs 4%, 
respectively; however, the improvement observed with CTD did not translate into longer 
survival.(23) 
 
Bortezomib-based therapies 
 Bortezomib plus melphalan and prednisone (VMP).  The combination VMP has been 
explored in the international VISTA (Velcade as Initial Standard Therapy) trial, which is the largest 
MP-based phase III study so far, evaluating a total of 682 patients. This study showed the 
superiority of VMP in comparison with the traditional MP for all efficacy endpoints: CR rate was 
30% vs 4% (P < 0.001), median TTP was 24 months vs 17 months (P < 0.001),(24) and the 3-year 
OS was 69% vs 54 %, (P = 0.0008).(25) Hematologic AEs were similar in the two groups. Grade 3-
4 peripheral sensory neuropathy was more frequent in the VMP group (14% vs 0%), as well as 
grade 3-4 gastrointestinal events (19% vs 5%). The rate of serious AEs in patients who received 
VMP was higher than in the control group (46% vs. 36%), but treatment-related deaths were similar 
(2% and 2%).(24,25) Today, VMP is considered a new standard of care for myeloma patients who 
are not candidates for ASCT. 
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Bortezomib plus thalidomide based therapies  
Bortezomib plus thalidomide and prednisone (VTP).  The new standard VMP has been 
compared to the VTP regimen in a randomized study. In both arms, bortezomib was administrated 
with one 6-week cycle of a twice weekly infusion (days 1, 4, 8, 11, 22, 25, 29, and 32) followed by 
five 5-week cycles of a weekly infusion (days 1, 8, 15 and 22). Response rates were similar: at least 
PR was 79% in both groups, with a CR rate of 22% vs 27%, respectively in the VMP regimen and 
VTP regimen. After a median follow-up of 22 months, there were no significant differences in terms 
of 2-year TTP (VMP 75% vs VTP 70%), PFS (VMP 71% vs VTP 61%) and OS (VMP 81% vs VTP 
84%). Grade 3-4 non hematological AEs were more frequent with VTP as compared to VMP, in 
particular cardiac toxicity (8.5% vs 0% P < 0.001), thromboembolic events (4% vs < 1%, P = not 
significant [NS]), and peripheral neuropathy (9% vs 5%, P = NS), resulting in a significantly higher 
rate of treatment discontinuation in the VTP arm (17% vs 8%, P = 0.03). Patients who received 
VMP had a higher rate of neutropenia (37% vs 21%, P = 0.003), thrombocytopenia (22% vs 12%, P 
= 0.03) and infections (7% vs < 1%, P = 0.01). VMP proved to be better tolerated than VTP, with no 
differences in survival, therefore confirmed as new standard of care for elderly myeloma 
patients.(26)  
 Bortezomib plus melphalan, prednisone and thalidomide (VMPT). A recent phase III 
trial compared the combination VMPT followed by maintenance with VT, with VMP. Response 
rates were superior with the four-drug regimen: at least PR rate was 89% vs 81% (P = 0.01), at least 
VGPR rate was 59% vs 50%, (P = 0.03), and CR rate was 38% vs 24% (P = 0.0008). Increase in 
response rate translated into an increase in survival: after a median follow-up of 17.8 months, the 2-
year PFS was significantly longer in the VMPT group (70% vs 58%, P = 0.008). No differences in 
OS were detected between the two groups, but follow-up is still short. Grade 3-4 neutropenia was 
more common among VMPT patients (38% vs 28%, P = 0.02), so were cardiac complications (10% 
vs 5%, P = 0.04). The incidence of other grade 3-4 AEs was similar in the two groups.(27) In both 
arms, bortezomib was initially administered with a twice-weekly schedule (1.3 mg/m
2
 on days 1, 4, 
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8, and 11). In order to evaluate whether both regimens could be further optimized by reducing 
toxicity, the study protocol was amended and bortezomib administration was then reduced to a 
once-weekly infusion (1.3 mg/m
2
 on days 1, 8, 15, and 22). There was a significantly reduced 
overall incidence of grade 3-4 peripheral neuropathy (8% versus 28%, P < 0.001) in the once-
weekly versus twice-weekly group, without any significant change in efficacy.(28) Of note, this is 
the first study to show the superiority of a 4-drug combination followed by maintenance over the 
most recent standard therapy VMP. Moreover, this study confirmed the higher efficacy and good 
tolerability of the once-weekly schedule of bortezomib. 
 
Lenalidomide-based therapies 
 Lenalidomide and high-dose dexamethasone (RD). In a phase III randomized trial 
RD resulted in a higher CR rate (21%) compared to high-dose dexamethasone alone, as well as in a 
significant improvement in 1-year PFS (77% vs 55%, P=0.02) and a trend towards a better OS 
(97% vs 93%, P=NS), but was associated with a higher incidence of grade 3-4 AEs (in particular 
neutropenia [14% vs 3%] and non-neutropenic infections [19% vs 10%]), that translated into an 
increase in treatment discontinuation.(29,30) Another open-label randomized trial compared RD 
with lenalidomide plus low-dose dexamethasone (Rd) as initial therapy for newly diagnosed 
patients. Interestingly, in this trail the use of high-dose dexamethasone in association with 
lenalidomide was not associated with an increased TTP and PFS, and the 2-year OS was 87% with 
Rd and 75% with RD (P < 0.001). Treatment with high-dose dexamethasone increased the number 
of early deaths and the rate of AEs, in particular thromboembolic events. Considering the better 
toxicity profile associated with low-dose dexamethasone, all patients enrolled in the RD group 
crossed over to Rd treatment. The landmark analysis at 4 months showed the impact of different 
treatment approaches: 3-year OS for patients who continued on primary therapy beyond 4 months 
was 79%, whereas it was only 55% in patients who stopped treatment after 4 months.(31) A 
subsequent subgroup analysis confirmed the good tolerability and the efficacy of Rd in the subset of 
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patients older than 70 years.(32) Considering the good tolerability and the efficacy of this regimen, 
Rd continued until progression can be considered a valuable option for patients older than 65 years.  
 Lenalidomide plus melphalan and prednisone (MPR). The European Myeloma 
Network phase III study compared MPR with standard MP. Patients were randomly assigned to 
receive MPR followed by lenalidomide maintenance therapy (MPR-R), or MPR followed by 
placebo maintenance, or MP followed by placebo maintenance. Responses were significantly higher 
with MPR-R: at least PR rate was 77% in the MPR-R arm, with at least VGPR in 32% of patients 
and CR in 16%, while the corresponding figures with MP were 50%, 12%, and 4% (P < 0.001). 
Similarly, 2-year PFS was considerably improved in patients who received MPR-R compared with 
those who received MP followed by placebo maintenance (55% vs 16%, P < 0.001). No differences 
were noted in the 1-year OS (92% in both arms). Grade 3-4 hematologic AEs were more frequent 
with MPR-R than with MP (neutropenia 71% vs 30%, and thrombocytopenia 38% vs 14%). The 
more common grade 3-4 non hematologic AEs were infections (10% of patients receiving MPR-R 
vs 8% of those receiving MP), and fatigue (5% vs 3% with MPR-R and MP, respectively). None 
patients in both groups experienced a grade 3-4 peripheral neuropathy.(33) These data suggest that 
MPR-R may be considered a new and valuable standard of care for patients older than 65 years or 
for younger patients not eligible for ASCT. 
The efficacy of the treatments described above have been summarized in Table 2. The most 
frequent grade 3-4 AEs associated with these regimens have been summarized in Table 3. 
 
Autologous transplant in elderly patients  
Patients older than 65 years, as well as those with significant comorbidities, are generally 
not considered candidates for standard melphalan 200 mg/m
2
 followed by ASCT. A randomized trial 
exploring the efficacy of high-dose chemotherapy and transplant in patients with newly diagnosed 
MM showed a significantly higher 5-year OS in patients younger than 65 years undergoing ASCT 
compared to elderly subjects (68 % vs 50 %, respectively; P = 0.008).(34) Two randomized studies 
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compared intermediate dose melphalan (Melphalan 100 mg/m
2
 - Mel 100) and reduced-intensity 
ASCT with standard MP. The first study included patients aged 65 to 70 years, and showed that 
reduced-intensity ASCT leads to better event-free survival (EFS) and OS as compared to standard 
MP.(37) The second study included patients aged 65 to 75 years, and compared reduced-intensity 
ASCT with both standard MP and with MPT: in this trial, PFS and OS were longer in patients 
treated with MPT compared with MP or Mel100, and no differences between MP and Mel100 were 
found.(20) A recent phase II trial evaluated the safety and efficacy of novel agents incorporated in 
both pre-transplant induction and post-transplant consolidation and maintenance, in patients aged 
65-75 years, who received reduced intensity ASCT (Mel100): the CR rate was 13% after induction 
with bortezomib, 43% after Mel100, and 73% during consolidation-maintenance with lenalidomide. 
During bortezomib induction, grade 3-4 toxicities included thrombocytopenia (17%), neutropenia 
(10%), peripheral neuropathy (16%) and pneumonia (10%). Lenalidomide consolidation-
maintenance was well tolerated, with no cumulative or persistent grade 3-4 neutropenia (16%) 
and/or thrombocytopenia (6%); pneumonia (5%) and cutaneous rash (4%) were the more frequent 
extra-hematologic AEs.(38) Data from these trials suggest that the reduced-intensity ASCT is a 
valuable approach for both elderly patients and younger subjects with pre-existing comorbidities, 
for whom full-dose chemotherapy and ASCT may be too toxic. A sequential approach, including 
bortezomib as induction, reduced intensity ASCT and  lenalidomide as consolidation-maintenance 
lead to a progressive improvement in response rates, by taking advantage of a subsequent exposure 
to different drugs.  
 
Role of maintenance therapy in elderly patients  
Only few studies on the role of maintenance therapy in elderly patients are available.  
Maintenance with VT has been tested in the Italian study comparing VMPT-VT vs VMP. An 
exploratory analysis performed on the 82 VMPT-VT patients who received at least 6 months of VT 
maintenance showed an improvement in CR rate from 58% after 9 cycles of VMPT to 62% after 6 
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months of VT maintenance.(27) Mateos and colleagues investigated the role of maintenance therapy 
with bortezomib plus prednisone (VP) vs bortezomib plus thalidomide (VT) in elderly patients 
respectively assigned to induction with VMP and VTP. An overall improvement in the CR rate was 
detected with maintenance treatment (from 25% up to 42%), and no significant differences in 
response rates between the two arms were seen (38% and 46%, respectively with VP and VT). After 
a median duration of maintenance of 13 months, there was a trend towards a lower TTP with VP 
compared with VT (1-year TTP:71% vs 84%; P=0.05), though no significant difference was found 
in terms of OS (89% vs 92%, respectively with VP and VT). (26). 
In the European Myeloma Network phase III study, after induction with MPR, patients were 
randomized to receive lenalidomide or placebo maintenance until progression: landmark analysis 
showed that the addition of lenalidomide maintenance to MPR decreased the risk of progression by 
69%. The survival advantage was also confirmed in the very elderly patient population older than 
75 years.(33) This is an unprecedented result, and it supports the positive role of maintenance with 
lenalidomide.  
 
Management of AEs 
Management of AEs plays a key role in optimizing the efficacy of treatment, especially in 
elderly patients. The studies described above showed that the toxicity associated to a regimen may 
jeopardize the efficacy of the treatment itself, and consequently may negatively affect survival rates. 
Indeed, despite the better results achieved with TD compared to MP, TD is more toxic, and this 
represents a essential limitation of that combination.(15) The efficacy of the treatments previously 
described should therefore be balanced against the toxicity. The National Cancer Institute Common 
Terminology Criteria (NCI-CTC) should be used to uniformly grade AEs.(35) On the basis of the 
seriousness of the event, physicians should take proper action. Generally, at the occurrence of any 
grade 4 or higher hematological or grade 3 or higher non-hematologic toxicities, treatment should 
be immediately withheld until the toxicity resolves to grade 1. Upfront reduction of the drug-doses 
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according to patients’ age must be considered, since older patients are likely to benefit more from a 
gentler approach (Table 4). Here, we report a description of the main AEs related to MM and linked 
to the use of novel agents, providing an overview of the possible specific interventions to manage 
AEs.  
 
Hematologic toxicities 
Neutropenia 
Neutropenia is quite frequent in MM patients treated with new drugs in combination with 
alkylating agents, but less frequent when they are used with dexamethasone alone.Using 
granulocyte-colony stimulating factor (G-CSF) is an efficacious and well tolerated method to 
decrease or prevent neutropenia. When neutropenia reaches grade 4 (neutrophilic count < 500/mm
3
) 
despite G-CSF, treatment should be suspended. Treatment can be restarted when the AE resolves to 
grade 2 (neutrophilic count ≥ 1000/mm3), but appropriate dose reduction are necessary. The greatest 
concern linked to neutropenia is the risk of infections. Prophylaxis with G-CSF is recommended to 
prevent febrile neutropenia in patients at high-risk on the basis of age, medical history, disease 
characteristics, and the expected myelotoxicity of the chemotherapy regimen. (36) 
 
Thrombocytopenia 
The use of bortezomib, lenalidomide, alkylating agents and their combinations are 
commonly associated with this AE, while treatment with thalidomide alone or plus steroids rarely 
causes thrombocytopenia. When thrombocytopenia reaches grade 4 (platelet count < 25,000/mm
3
), 
treatment should be interrupted; it can then be restarted when the event resolves to grade 2 (platelet 
count < 50,000/mm
3
), with appropriate dose-reduction of the suspected drug. (36) 
 
Anemia 
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Anemia is generally related to MM, especially in case of recurrent or refractory disease.(37) 
In order to prevent functional iron or vitamin deficiency and to support increased erythropoiesis, a 
prompt monitoring of the iron and vitamin status is necessary. Erythropoiesis-stimulating agents 
(ESAs) are recommended to manage treatment-related anemia, generally when the haemoglobin 
concentration is less than 10 g/dL and no improve despite response to therapy has been shown; 
however, treatment can begin earlier at physicians’ discretion (haemoglobin 10 to 12 g/dL) for 
patients with heart disease or those who have difficulties undertaking regular daily activities. The 
dose of ESAs should be adjusted to keep the hemoglobin concentration around 11 to 12 g/dL, to 
avoid blood transfusion and anemia-related symptoms. In case the hemoglobin concentration is 
greater than 12 g/dL, serious heart problems may occur and the risk of thrombosis should be taken 
into account.(38) 
 
Extra-hematologic toxicities 
Infections 
The disease itself can cause impairment in immune function, with consequent increase in 
risk of infections. The risk is therefore higher in case of active disease but decreases when the 
patient responds to therapy. Treatment, and in particular the use of high-dose dexamethasone and 
myelotoxic drugs that can cause neutropenia, increases the risk of infections.  Herpes zoster is a 
possible complication related to bortezomib administration.(39) 
For patients receiving high-dose dexamethasone, elderly patients, patients with 
comorbidities that increase the risk of infections (i.e. chronic obstructive pulmonary disease, 
diabetes, renal function impairment), and for patients with an increased infection rate, routine oral 
antibiotic prophylaxis could be considered at least for the first 3 months of therapy. Trimethoprim-
sulphamethoxazole should be used at least during the first 2-3 months of chemotherapy or during 
steroid administration.(39) For all patients receiving treatment with bortezomib, acyclovir 
prophylaxis demonstrated effective in decreasing the incidence of zoster reactivation.(24)  
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Peripheral neuropathy 
Treatments with bortezomib and thalidomide can cause peripheral neuropathy. Incidence of 
grade 3-4 neuropathy is similar in thalidomide- or bortezomib-based regimens, in both relapsed and 
newly diagnosed settings. Both thalidomide and bortezomib-related neuropathies are cumulative 
and linked to the dose administered. While bortezomib interruption relieves neuropathic symptoms 
(40), discontinuation of thalidomide generally does not improve the treatment-related 
neuropathy.(41) By contrast, grade 3-4 peripheral neuropathy rarely occurs in patients treated with 
lenalidomide, and lenalidomide has been administered to patients who have received prior 
thalidomide treatment without further deterioration of preexisting thalidomide-related 
neuropathy.(42,43)   
To date, there are no pharmacological drugs able to effectively relieve neuropathic 
symptoms, and modifying promptly the schedule of the drug or reducing the dose is the most 
effective measure to treat this condition. Patients should be instructed on how to recognize 
peripheral neuropathy, and to promptly search for medical care. For bortezomib-treated patients, in 
case of grade 1 with pain or grade 2 peripheral neuropathy, a dose reduction of bortezomib to 1.0 
mg/m
2 
is recommended; for grade 2 with pain or grade 3 peripheral neuropathy interruption of 
bortezomib is recommended until peripheral neuropathy resolves, and then it can be restarted at 0.7 
mg/m
2
; when peripheral neuropathy reaches grade 4, prompt interruption of bortezomib is highly 
recommended.(44)  The recent phase 3 study comparing VMPT-VT vs VMP suggests that reducing 
bortezomib schedule from a twice-weekly infusion (starting dose 1.3 mg/m
2 
twice a week for a total 
of 4 doses every treatment cycle) to a once-weekly infusion (same dose 1.3 mg/m
2
 once weekly for 
a total of 4 doses every treatment cycle) is an optimal alternative. Subsequent dose reductions are 
1.0 mg/m
2
 once weekly and, if necessary, 0.7 mg/m
2
 per week can be the following steps.(28) 
For patients treated with thalidomide, in case of grade 1 sensory neuropathy, the assigned 
dose should not be modified, while, if it reaches grade 2, thalidomide dose should be reduced by 
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50%; if neuropathy reaches grade 3, discontinuation is necessary. Thalidomide can then be resumed 
at a lower dose when the event improves to grade 1.(41)  
 
Thrombosis 
The incidence of VTE in MM patients ranges from 3% to 10%, and is particularly related to 
the type of drug used to treat the patient. Bortezomib was never found to be linked to an increased 
risk of VTE, nor were thalidomide or lenalidomide alone. Conversely, the risk of VTE considerably 
increases when dexamethasone or chemotherapy are added to IMIDs, particularly in newly 
diagnosed patients, while the risk of VTE at relapse is lower, especially in thalidomide-treated 
patients.(45)  
So far, there are no data on which is the best thromboprophylaxis to use in MM patients 
treated with IMIDs. The Italian Myeloma Network GIMEMA designed a phase III study to address 
this question and to compare the efficacy and safety of low-molecular-weight heparin (LMWH), 
low-fixed-dose warfarin (1.25 mg/day), or low-dose aspirin as VTE prophylaxis in newly diagnosed 
patients, who received primary induction with thalidomide-based regimens. Preliminary results 
showed that serious VTE episodes were equally reported in the ASA and LMWH groups (3.6% of 
patients vs 2.7% of patients, respectively, P = 0.17), while the incidence of VTE was significantly 
higher in  patients receiving warfarin prophylaxis compared to LMWH patients (6.4% of patients vs 
2.7% of patients, respectively, P = 0.02).(46)  These results are consistent with the VTE incidence 
detected in another phase III trial comparing ASA with LMWH, where newly diagnosed patients 
were treated with Rd induction (VTE rate 2% vs 1% respectively, P = NS).(47) 
Baseline coagulation tests and screening for VTE are not required in asymptomatic patients. 
Presence of risk factors for thrombosis in MM patients treated with IMIDs should be evaluated in 
order to choose the best antithrombotic prophylaxis. The risk factors to determine whether a patient 
should be considered at high risk of thromboembolism can be classified as follows: individual risk 
factors that include previous history of VTE, inherited thrombophilia, age, obesity, comorbidities 
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such as cardiac disease, chronic renal disease, diabetes, infections, immobilization, presence of 
central venous catheter and surgical procedures; myeloma-related risk factors  including diagnosis 
and hyperviscosity; therapy-related risk factors, that is to say high-dose dexamethasone, 
doxorubicin, or multiagent chemotherapies, or immunomodulatory compounds. Patients with 
therapy-related risk factors should be considered per se to be at high-risk. If none or one individual 
or myeloma-related risk factor is present, aspirin (81-325 mg/day) is the most appropriate 
prophylaxis. If two or more individual or myeloma-related or therapy-related risk factors are 
detected, LMWH (equivalent of enoxaparin 40 mg/day) or full-dose warfarin (international 
normalized ratio [INR] target 2-3) should be used. Prophylaxis is generally recommended for at 
least the first 4-6 months. Patients who experienced VTE during treatment can either continue the 
treatment or suspend it and then start it again after improvement/resolution. Patients who 
experienced VTE despite taking aspirin should receive LMWH; patients treated with prophylactic 
LMWH should switch to therapeutic doses.(45)   
 
Renal failure 
Factors involved in the pathogenesis of renal failure include the capacity of the light-chain 
component of the immunoglobulin to cause proximal tubular damage, dehydration, hypercalcemia, 
hyperuricemia, infections, and use of nephrotoxic drugs. Appropriate hydration, urine 
alkalinization, treatment of hypercalcemia, hyperuricemia and infections, and active therapy with 
rapid decrease of the proteinuria prevent further deterioration of the renal function.(48) In case of 
renal failure, no dose modifications of thalidomide and bortezomib are needed. Lenalidomide dose 
reductions are instead mandatory depending on the creatinine clearance values: between 30 and 60 
mL/min, the recommended dose of lenalidomide is 10 mg per day; with a value lower than 30 
mL/min, the recommended dose is 15 mg every other day for patients not requiring dialysis; if 
creatinine clearance is inferior to 30 mL/min and the patient requires dialysis, lenalidomide dose is 
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5 mg per day after dialysis on dialysis days. In patients receiving lenalidomide-containing therapies, 
a constant monitoring of the hematologic function is necessary, particularly in the early cycles.(49)  
 
Bone disease 
Skeletal complications, such as vertebral compression or collapse from osteoporosis, and pain 
arising from these complications, are common in MM patients. Systemic analgesia, local measures 
(like radiotherapy), and obviously chemotherapy, acting against the disease itself,  are all important 
to relieve the pain.(50)  
For what concerns local measures, radiotherapy is effective for bone pain relief.(51,52) 
Vertebroplasty is another effective method against local pain. It strengthens the bone, but still does 
not restore vertebral height.(53)  A recent randomized phase III study of balloon kyphoplasty 
detected a considerable reduction in back pain and disability at one month after procedure.(54)  
Different types of analgesia are available to relieve bone pain, such as simple non-opioid analgesics, 
particularly indicated in case of mild to moderate pain. Weak opioids should be used when non 
opioid analgesic are inefficacious, but a particular caution should be paid to their administration, 
since they may cause confusion, drowsiness, and eventually constipation. In case of moderate to 
severe pain, strong natural opioids or also synthetic opioids can be administered.(55) 
Bisphosphonate are recommended to prevent new bone lesions and skeletal events.(56) 
Recently, a survival benefit has been reported in newly diagnosed patients receiving zolendronic 
acid.(57) Given the potential risk of osteonecrosis of the jaw, a comprehensive dental examination 
and appropriate preventive dentistry is required.(58)  
 
Gastrointestinal AEs 
Gastrointestinal side effects are rarely related to myeloma but they are commonly linked to 
therapy. Thalidomide treatment may usually lead to constipation, while the use of lenalidomide 
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most frequently causes diarrhea. Both constipation and diarrhea have been reported with 
bortezomib-based regimens. 
Patients suffering from diarrhea should maintain a high fluid intake; antidiarrheal drugs can 
be used, after exclusion of active infections. In case of grade 3-4 toxicity, a 50% dose reduction of 
the suspected drug is recommended. Patients should maintain a high fluid intake in case of 
constipation as well. An additional help may be a high fiber diet, if medically appropriate. When 
necessary, stool softeners and osmotic laxatives can be administered.  
 
Dermatologic AEs 
The use of both thalidomide and lenalidomide is often associated with dermatologic 
toxicity, most frequently rash, dry skin and mouth and atrophic lesions. These side effects are 
usually mild to moderate and they can be easily managed. Toxic epidermic necrolysis and Stevens-
Johnson syndrome are more serious, but fortunately quite uncommon.(41) Bortezomib-based 
treatments only rarely can cause dermatologic side effects: the highest rate was reported with the 
association of bortezomib and pegylated-liposomal-doxorubicin in relapsed patients, where the 
main AE was hand-foot syndrome related to pegylated-liposomal-doxorubicin.(59,60)  
Physicians should be very cautious while co-administering thalidomide or lenalidomide with 
agents with known dermatologic toxicity, such as sulfonamides, allopurinol, cotrimoxazole. In these 
cases a careful monitoring is needed. When mild toxicities occur, temporary discontinuation is 
generally the best method to solve the rash. If necessary, treatment should begin with 
antihistamines; if rash persists, low-dose prednisone (10-20 mg/day for up to 14 days) should be 
added. In case of severe toxicity, the treatment should be interrupted until complete resolution and 
with 50% dose reductions. After toxic epidemic necrolysis or the Stevens-Johnson syndrome, re-
administration of the responsible drug is contraindicated. 
 
Conclusion 
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The combination of conventional chemotherapy or low-dose dexamethasone with new drugs 
has substantially changed the treatment paradigm for patients with MM, increasing therapeutic 
options available for this disease. Randomized phase III studies have shown that MPT, MPV and 
MPR-R proved to be more effective than the traditional treatment with MP; hence, they can now be 
regarded as new standards of care for patients ineligible for ASCT. The four-drug combination 
VMPT followed by VT maintenance recently showed to be a more effective regimen than VMP,  
and represents another valuable option for elderly MM patients. Preliminary results on Rd are also 
encouraging, but they still need to be further supported and confirmed in comparative studies with 
three- and four- drug combinations. 
Physicians have now a wider variety of treatment options available. They can tailor more 
personalized therapies according to the patients’ characteristics and comorbidities, by balancing 
efficacy and toxicity of the treatment regimens. This improves both the quality of life and outcome, 
and subsequently represents a great advantage for the patient.  
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Table 1. Diagnostic criteria, baseline evaluation and staging system 
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At least 10% clonal bone marrow plasma cells plus serum and/or urinary monoclonal protein 
                                                                    plus  
Myeloma-related organ dysfunction, CRAB criteria:  
       -    C: hypercalcemia (serum calcium >11.5 mg/dl, [2.65 mmol/l]) 
       -    R: renal insufficiency (serum creatinine > 2 mg/dl, [1.73 mmol/l]) 
       -    A: anemia (hemoglobin < 10 g/dl, [12.5 mmol/l] or > 2 g/dl [1.25 mmol/l]  below the  lower   
limit of normal) 
       -    B: bone disease (lytic lesions, severe osteopenia or pathologic fractures) 
 29 
B
a
se
li
n
e 
ev
a
lu
a
ti
o
n
 
 
- medical history 
-  physical examination 
- blood test: complete blood count, calcium creatinine, serum albumin, 2-microglobulin, 
lactate dehydrogenase serum electrophoresis with immunofixation, quantification of serum 
monoclonal protein, measurement of free-light chains, immunoglobulins 
- urine test: urine protein electrophoresis with immunofixation, quantification of monoclonal 
protein, measurement of free-light chains  
- bone marrow testing: trephine biopsy, aspirate of bone marrow cells and for fluorescent in 
situ hybridization of t(4;14), t(14;16) and 17p13 deletion 
- imaging: skeletal survey, magnetic resonance imaging of axial skeleton if skeletal survey is 
negative  
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International Staging System: 
        -    Stage I:   serum 2-microglobulin < 3.5 mg/l and serum albumin ≥ 3.5 g/dl  
        -    Stage II:  serum 2-microglobulin < 3.5mg/l and serum albumin < 3.5 g/dl or  
               serum 2-microglobulin 3.5 to <5.5 mg/l   
        -   Stage III: serum 2-microglobulin ≥5.5mg/l 
 
 
 
 
 
 
 
 
 
 
Table 2.  Efficacy of regimens used as a front-line treatment in elderly patients with multiple myeloma 
 
 
N CR ≥PR PFS/EFS/TTP  OS                                           Reference 
Thalidomide-based        
TD  
T: 200 mg 
D: 40 mg d 1-4, 15-
18 for a 28-day cycle 
 for 9 cycles 
145 2% 68% 41% at 24 mo 
61% at 24 
mo 
Ludwig et al 
 15 
 
 30 
MPT 
M: 4 mg/m2 d 1-7 
P: 40 mg/m2 d 1-7  
T: 100 mg/day  
for six 4-week cycles 
 
Maintenance: 
T: 100 mg/day  
129 16% 76% 50% at 22 mo 
50% at 45 
mo 
Palumbo et al 
17,18 
 
 
 
 
 
 
 
 
MPT 
M: 0.25 mg/Kg d 1-4 
P: 2 mg/kg d 1-4 
T: 400 mg/day  
for 12 6-week cycles 
125 13% 76% 50% at 28 mo 
50% at 52 
mo 
Facon et al 
19 
MPT 
M: 0.25 mg/Kg d 1-4 
P: 2 mg/kg d 1-4 
T: 100 mg/day  
for 12 6-week cycles 
113 7% 62% 50% at 24 mo 
50% at 44 
mo 
Hulin et al
20 
MPT 
M: 0.25 mg/Kg d 1-4 
P: 100 mg d 1-4 
T: 200-400 mg/day  
for a 6-week cycle 
until plateau 
 
Maintenance: 
T: 200 mg/day  
182 6% 42% 50% at 16 mo 
50% at 29 
mo 
Gulbrandsen et al
 16
 § 
MPT 
M: 0.25 mg/Kg  
P: 1 mg/ days 1-5 
T: 200 mg/day  
for eight 4-week 
cycles 
 
Maintenance: 
T: 50 mg/day  
165 66% 
67% at 24 
mo 
29% at 24 mo 
Wijerman
s et al 
21 
 
MPT
 
CTD  
C: 500 mg d 1, 8, 15 
T: 100-200 mg/day 
D: 40 mg d 1-4, 12-
15  
for a 3 week cycle  
450 21% 91% ND ND Morgan et al 
23 
Bortezomib-based        
VMP 
M: 9 mg/m2 d 1-4 
P: 60 mg/m2 d 1-4 
V: 1.3 mg/m2 
d 1, 4, 8, 11, 
22, 25, 29, 32 
for the first 
four 6-week 
cycles; d 1, 8, 
22, 29 for the 
subsequent 
five 6-week 
cycles 
344 30% 71% 
50% at 22 
mo 
70% at 36 mo 
M
ateos et al 
25
 
VMP 
M: 9 mg/m2 d 1-4 
P: 60 mg/m2 d 1-4 
V: 1.3 mg/m2 d 1, 8, 
15, 22 
257 24% 81% 70% at 36 mo 
87% at 36 
mo  
Palumbo et al
 27 
VMP 
M: 9 mg/m2 d 1-4 
P: 60 mg/m2 d 1-4 
V: 1.3 mg/m2 twice 
weekly (d 1, 4, 8, 11; 
125 22% 81% 71% at 24 mo 
81% at 24 
mo 
Mateos et al 
26 
 31 
22, 25, 29, and 32) 
for one 6-week cycle, 
followed by once 
weekly (d 1, 8, 15, 
and 22) for five 5-
week cycles 
 
Maintenance: 
V:1.3 mg/m2 twice 
weekly on days 1, 4, 
8, 11, every 3 months 
T: 50 mg/d  
Bortezomib- and Thalidomide-
based  
      
VTP 
T: 100 mg/day 
P: 60 mg/m2 d 1-4 
V: 1.3 mg/m2 twice 
weekly (d 1, 4, 8, 11; 
22, 25, 29 and 32) for 
one 6-week cycle, 
followed by once 
weekly (d 1, 8, 15 
and 22) for five 5-
week cycles  
 
Maintenance: 
V:1.3 mg/m2 twice 
weekly on days 1, 4, 
8, 11, every 3 months 
P: 50 mg every other 
day 
128 27% 79% 61% at 24 mo 
84% at 24 
mo 
Mateos et al 
26 
VMPT 
M: 9 mg/m2 d 1-4 
P: 60 mg/m2 d 1-4 
V: 1.3 mg/m2 d 1, 8, 
15, 22 
T: 50 mg d 1-42 for 
nine 5-week cycles  
 
Maintenance: 
 Bor: 1.3 mg/m2 
every 15 days 
T: 50 mg/day  
254 38% 89% 60% at 36 mo 
88% at 36 
mo 
Palumbo et al 
27 
Lenalidomide-based        
MPR 
M:0.18-0.25 mg/kg d 
1-4 
P: 2 mg/kg d 1-4 
R: 5-10 mg d 1-21  
for nine 4-week 
cycles 
 
Maintenance: 
R: 10 mg d 1-21 
152      16% 45% 55% at 24 mo 
92% at 12 
mo 
Palumbo et al
33
 
Rd 
R: 25 mg d 1-21 
d: 40 mg d 1, 8, 15, 22  
for a 4-week cycle 222 4% 68% 50% at 25 mo 87%% at 24 mo 
Rajku
mar et al 
31 
 
 32 
N indicates number of patients;  CR, complete remission; PR partial response; PFS, progression-free survival; 
EFS, event-free survival; TTP, time to progression; OS, overall survival; M, melphalan; P, prednisone; T, thalidomide;  
V, bortezomib; R, lenalidomide; C, cyclophosphamide; D, high-dose dexamethasone; d, low-dose 
dexamethasone; MPT, melphalan-prednisone-thalidomide; VMP, bortezomib-melphalan-prednisone; VTP, bortezomib-
thalidomide-prednisone; VMPT, bortezomib-melphalan-prednisone-thalidomide; CTD, cyclophosphamide-thalidomide-
dexamethasone; MPR, melphalan-prednisone-lenalidomide; NA, not available. § Updated information was presented at 
the meeting (American Society of Clinical Oncology, European Haematology Association and American Society of 
Hematology congress). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.    Safety (grade 3-4 adverse events) of regimens used as front-line treatment in elderly patients with 
multiple myeloma 
 
Regimen N Neutropenia  Thrombocytopenia Infection Peripheral 
neuropathy 
VTE Ref 
 33 
Thalidomide-based        
TD 145 3% 1% 13% NA 10% Ludwig et al
15 
 
MPT 129 16% 3% 10% 8% 9% Palumbo et 
al
17,18 
MPT 125 48% 14% 13% 6% 12% Facon et al 
19 
MPT 113 23% NA NA 20%* 6% Hulin et al 
20 
MPT 165 NA NA 28% 23% 3% Wijermans et 
al 
21
  
Bortezomib-based        
VMP 344 40% 38% 10% 13% 1% S Miguel et al 
24
, Mateos et al 
25  
VMP 257 28% 20% 9% 8% 2% Palumbo et al
 
27
  
VMP 125 37% NA 7% 5% NA Mateos et al 
26 
Bortezomib- and 
Thalidomide-based 
       
VTP 128 21% NA% <1% 9% NA Mateos et al 
26 
VMPT 254 38% 22% 13% 12% 5% Palumbo et al 
27
  
Lenalidomide-based        
Rd 220 20% 5% 9% 2% 12% Rajkumar et al 
31
 
MPR 152 70% 37% 10% 0% 5% Palumbo et al
33
 
 
N indicates number of patients; MPT, melphalan-prednisone-thalidomide; VMP, bortezomib-melphalan-prednisone; 
VTP, bortezomib-thalidomide-prednisone; VMPT, bortezomib-melphalan-prednisone-thalidomide; CTD, 
cyclophosphamide-thalidomide-dexamethasone; MPR, melphalan-prednisone-lenalidomide; NA, not available. 
*Grade 2-4.  
 
 
 
 
 
 
 
 
 
 
 
Table 4.   Recommended age-adjusted dose reduction 
 
65-75 years > 75 years Further dose reduction 
Dexamethasone  40 mg weekly 20 mg weekly 10 mg weekly 
 34 
Melphalan  0.25 mg/kg daily days 1-4 0.18 mg/kg daily days 1-4 0.13 mg/kg daily days 1-4 
Thalidomide  200 mg daily 100 mg daily 50 mg daily 
Lenalidomide (plus dexamethasone)  25 mg daily days 1-21 15 mg daily days 1-21 10 mg daily days 1-21 
Lenalidomide (plus melphalan-
prednisone)  
10 mg daily days 1-21 5 mg daily days 1-21 5 mg every other day days 
1-21 
Bortezomib 1.3 mg/m
2
 twice weekly 1.3 mg/m
2
 once weekly 1.0 mg/m
2
 once weekly 
 
 
 
 
 
